Alterity Therapeutics CEO to present lead asset ATH434 for Parkinsonian disorders at a webinar.
Alterity Therapeutics, a biotech firm specializing in treating neurodegenerative diseases, will present at the MST Access 'Hidden Gems in Life Sciences' webinar on June 12 (US) or June 13 (Australia). CEO David Stamler will give a company overview, discussing lead asset ATH434, which treats various Parkinsonian disorders and is being evaluated in two Phase 2 clinical trials for Multiple System Atrophy. Alterity also has a broad drug discovery platform for neurological diseases.
June 12, 2024
4 Articles